Validated in vitro and ex vivo screening platform for hair follicle aging
Epibiotech offers a specialized in vitro and ex vivo screening platform for evaluating hair follicle and scalp health, enabling medium-throughput screening of pharmaceuticals targeting cellular senescence and aging-related changes.
Overview
Epibiotech presents a cutting-edge in vitro and ex vivo screening platform designed to evaluate hair follicle and scalp health. This platform facilitates medium-throughput screening of pharmaceuticals, focusing on identifying active ingredients targeting cellular senescence and other aging-related changes in the follicular environment. By combining in vitro cell viability assessments with ex vivo cultured human hair follicles, the platform offers a comprehensive approach to hair follicle aging research.
Technical specifications
- In vitro assessments: Enable hair follicle cell viability evaluation and functional analysis, allowing for effective medium-throughput screening.
- Ex vivo validation: Utilizes proprietary ex vivo hair follicle culture models for follow-up validation of selected candidates.
- Flexible and cost-effective: Offers reproducible and timely results tailored to pharmaceutical industry expectations.
- CRO expertise: Extensive experience in hair follicle-based efficacy testing, including hair growth evaluation and alopecia studies.
Technology readiness level
The technology is currently at TRL 4, indicating that it has been validated in a lab environment. Future validation involves a preparation phase of 3–4 weeks, with in vitro assays taking 2–3 weeks for fewer than 5 compounds and approximately 1 month for more than 5. Ex vivo experiments require 1–2 months, followed by a 2-week data analysis period.
About Epibiotech
Epibiotech is a South Korean biopharmaceutical company specializing in the development of innovative treatments for alopecia. The company leverages a proprietary AI-driven drug discovery platform, Hair.I., which integrates a large genomic database, single-cell analysis, and AI screening to identify novel hair loss targets. Their research focuses on advanced modalities, including autologous and allogeneic dermal papilla cell therapies and neutralizing antibody treatments, designed to stimulate hair follicle regeneration and address the underlying causes of hair loss such as androgenetic factors.
These therapeutics provide targeted solutions for patients suffering from hair loss, aiming to offer more effective, science-based restoration compared to conventional treatments. By combining its drug development pipeline with non-clinical CRO expertise for efficacy evaluation, Epibiotech supports the advancement of hair science from discovery to clinical trials. The company has reached significant milestones, including initiating clinical trials for its lead cell therapy candidate, EPI-001, and securing recognition through international biotech innovator awards.
delivered to your inbox.